Implications of helminth immunomodulation on COVID-19 co-infections by Chacon, Nathalie et al.
University of Texas Rio Grande Valley 
ScholarWorks @ UTRGV 
School of Medicine Publications and 
Presentations School of Medicine 
7-2021 
Implications of helminth immunomodulation on COVID-19 co-
infections 
Nathalie Chacon 
The University of Texas Rio Grande Valley 
Leonor Chacin-Bonilla 
Italo M. Cesar 
Follow this and additional works at: https://scholarworks.utrgv.edu/som_pub 
 Part of the Public Health Commons 
Recommended Citation 
Chacon N, Chacin-Bonilla L, Cesari IM.. Implications of helminth immunomodulation on COVID-19 co-
infections. Life Res. 2021;4(3):26. doi:10.53388/life2021-0502-309 
This Article is brought to you for free and open access by the School of Medicine at ScholarWorks @ UTRGV. It has 
been accepted for inclusion in School of Medicine Publications and Presentations by an authorized administrator 






Submit a manuscript: https://www.tmrjournals.com/lr 1 
REVIEW 
Implications of helminth immunomodulation on COVID-19 co-
infections 
 
Nathalie Chacon1 *, Leonor Chacin-Bonilla2, Italo M. Cesari3 
 
1School of Medicine. Department of Public Health. University of Texas Rio Grande Valley, Edinburg, USA. 2Institute of Clinical 
Research. Zulia State University, Maracaibo, Venezuela. 3Immunoparasitology Laboratory, Center for Microbiology and Cell 
Biology, Venezuelan Institute of Scientific Research, Altos de Pipe, Venezuela. 
 
*Corresponding to: Nathalie Chacon. School of Medicine. Department of Public Health. University of Texas Rio Grande 
Valley, Edinburg TX 78572, USA. E-mail: natychacon2004@gmail.com/nathalie.chacondealvarez@utrgv.edu. 
 
Abstract 
Coronavirus disease 2019 (COVID-19) and helminths infections can be in a synergistic epidemic in developing and 
suburban areas of industrialized countries. The coinfected hosts will derive a parasite-specific Th2 innate and 
adaptive immune response with CD4+ T cells, eosinophils, interleukin-4, interleukin-5, and interleukin-10. In the 
early stages of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection, virus-specific Th1 
cytotoxic CD8+ T cell, interleukin-6, interferon-γ, and interleukin-27 by lung are keys in controlling viral replication 
in the lung epithelial cells and limiting the pathology to other organs, like the intestine. CD4+ and CD8+ T cells are 
associated with protective immunity against and during COVID-19. However, viral evasion mechanisms occur. 
Interference of the interferon-γ secretion, like in helminths immunomodulation, can contribute to COVID-19 severity. 
Immunomodulation can result in mild, moderate, or severe COVID-19 depending on which helminth is coinfecting 
by regulating or avoiding host cytokine and pro-inflammatory response, decreasing viral load, and affecting vaccine-
induced antibody response. We discuss the implications of immunomodulation on COVID-19 caused by helminth 
co-infection and for public health in the context of COVID-19 vaccine use in helminth endemic zones. 
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Intestinal parasite co-infections are current in 
underdeveloped countries [1, 2] and areas of developed 
countries [3]. Studies of intestinal parasites in 
Venezuela for decades reveal high rates of infection. 
These results demonstrated a high prevalence of 
intestinal parasites (Entamoeba histolytica, Entamoeba 
coli, Trichiura trichuris, and Ascaris lumbricoides), [4–
6], emerging pathogens, Cryptosporidium spp. [7] and 
Cyclospora cayetanensis [8–10] and the most common 
zoonotic human protozoa, Blastocystis spp. [11]. Soil-
transmitted helminths (STH), Ascaris lumbricoides, 
Toxocara spp., Taenia sp., and Strongyloides have been 
reported in suburban areas of the US-Mexico 
borderlands, inner cities, and the Appalachia area of the 
United States of America [12].  
Helminths have systemic immunomodulatory effects 
triggered by their excretory/secretory helminth (E/S) 
products [13, 14] and may influence the severity of 
other infections. The host Th2 phenotype of the immune 
response mediated by regulatory T cells [15] can 
expulse the helminth parasite. However, established 
helminths mostly have a well-tolerated chronic 
infection by modulating the host immune response as a 
parasite survival mechanism [16]. Diverse species of 
helminths can infect humans. Human or zoonotic 
helminth parasites can live in the intestine, in organs 
such as the liver, lung, eye, and skin, in a specific 
environment, or  blood vessels. The host immune 
response against the helminth will be different in each 
one of these immunological microenvironments [14]. 
Extracellular (most intestinal helminths) and 
intracellular pathogens (viral agents) will induce 
different immune responses. Consequently, in cases of 
co-infection, host responses against either of the 
infecting pathogens can result in impaired or cross-
regulated. The immune regulation documented in co-
infections can result in either an increase of pathology 
[17] or protection [18] in the natural history of the 
second infection.  
Coronavirus disease 2019 (COVID-19) infections in 
developing countries will be in a synergistic epidemic 
with helminth neglected tropical diseases, called 
syndemic [19]. The immune regulation of intestinal 
helminth infection in humans coinfected by severe acute 
respiratory syndrome coronavirus type 2 (SARS-CoV-
2), the pathological or protective consequences in the 
natural history of the viral infection, and its possible 
implications in vaccine efficacy in helminth endemic 




Helminths are extracellular and multicellular organisms 
that can parasite a host by crossing epithelial barriers. 
Helminths can disrupt the epithelial layer and initiate 
the cascade of inflammatory events [20].  
Intestinal helminths can be transmitted orally by the 
ingestion of eggs or by skin penetration of larvae. The 
entry to the human body and the type of parasite 
(zoonotic or not) contribute to defining the pattern of the 
human immune response. The life cycle in the human 
body is in organs (intestine, lungs, liver, skin, vessels) 
and cellular tissues (endothelial, epithelial, and 
neuronal).  
Helminths' damage to tissues is followed by an 
inflammatory microenvironment and a cascade of 
events triggered by the helminth's E/S products [13, 21]. 
The most common E/S products in helminths are 
enzymes (e.g. proteases, glycolytic enzymes), protease 
inhibitors, venom allergen homologs, stress proteins, 
and lectins [22–25]. Helminth E/S products are 
responsible for the induction of Th2 immune 
responsiveness [14, 26].  
The first immune response to helminths is the innate 
immunity type 2 response [26–28]. The leaders of this 
response are the type Th2 innate lymphoid cells (ILC2s). 
ILC2s, mast cells, basophils, γδ+ T cells, neutrophils, 
and dendritic cells (DCs) are activated by the alarmin 
type of cytokines released by epithelial cells [26, 28]. 
The recruitment of hematopoietic stem/progenitor cells 
by alarmins, interleukin (IL)-25, IL-33 and thymic 
stromal lymphopoietin to initiate a type 2 immune 
response starts upon penetration of the parasite through 
the epithelial barriers. The anti-helminth adaptive 
immune response starts upon the release of type 2 
cytokines (IL-4, IL-5, and IL-13) by ILC2s. Three 
immune cells types will be the protagonist of this 
response: lymphocyte type 2 cells (T helper Th2), 
macrophage type 2, and immunoglobulin E (IgE)-
producing B cells [26]. 
The macrophage type 2 and eosinophils' activity can 
eventually result in the expulsion of the parasites and 
the healing of the affected epithelial tissues. Whenever 
the parasite cannot be eliminated, the granuloma can 
contain the infection. Type 2 immune response can 
promote tolerogenic responses for adult schistosomes. 
For instance, hepatic granuloma around the eggs will 
permit the survival of Schistosoma in the host and 
chronic disease status is maintained for several years 
[29].  
 
SARS-CoV-2 infection  
 
Host cells penetration by SARS-CoV-2 occurs in 
epithelial cells located in the oropharyngeal zone, lungs, 
gut, and other body tissues using the surface 
angiotensin-converting enzyme receptor 2 (ACE2) and 
the transmembrane serine protease 2 [30]. Viruses, 
having DNA or RNA genome structures to replicate, are 
obligated intracellular organisms. The SARS-CoV-2 
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spike (S) protein by the human ACE2 receptor. The 
SARS-CoV-2 will release its genomic material in the 
cytoplasm and start to translate into proteins. The 
subgenomic proteins, membrane (M) protein, spike (S) 
glycoprotein, and envelope (E) protein will be 
separately synthesized in the endoplasmic reticulum and 
then moved to the endoplasmic reticulum-Golgi 
intermediate compartment to join with the nucleocapsid 
(N) protein. N protein will meet other proteins and form 
vesicles that will be exported by exocytosis [30].  
The N protein of SARS-CoV-2 is responsible for the 
initial induction of the “cytokine storm” now called 
early inflammatory phase [31] (IL-6, IL-10, IL-1β, 
granulocyte-macrophage colony stimulatory factor, 
tumor necrosis factor-alpha (TNF-α), interferon (INF)-
γ) [31, 32]. A hypothesis about the possible limitation 
of COVID-19 severity has been discussed by others. 
This hypothesis is about the idea of avoiding the 
cytokine storm [18]. The multisystem inflammatory 
syndrome can be seen in children infected with COVID-
19 (MIS-C) and for adults (MIS-A). It is part of the 
multisystem inflammatory phase and is characterized by 
peak levels of immunoglobulin G (IgG), secondary 
infections, and many autoimmune events [31]. The 
helminth tolerogenic response could modulate the 
exaggerated immune responses by increasing IL-10 
levels.  The helminth E/S products can increment IL-
10 and are released during both phases, the early 
inflammatory and the multisystem inflammatory [18]. 
Non-structural proteins (NSP) from SARS-CoV-2 
are used by the virus in evasion mechanisms. NSP-1 can 
suppress the work of INF through host translational 
machinery inactivation [33]. NSP-16 suppresses the 
work of INF through host translational machinery 
inactivation and the global mRNA splicing in SARS-
CoV-1 infected cells, acting as a host virulence factor 
[33]. And the global mRNA splicing in SARS-CoV-2 
infected cells, acting as a host virulence factor [33]. 
SARS-CoV-2 by itself can also reduce CD3+, CD4+, 
CD8+ T lymphocyte counts. Critical patients reflect the 
severity of COVID-19 with low counts in CD8+ T 
lymphocytes [34]. CD8+ T cells are important for viral 
clearance by recognizing conservative regions on 
viruses and elicit a protective response [34–36]. 
Older individuals, people with linked ACE2 
expression or activity disorders (pre-diabetes, diabetes, 
obesity, chronic hepatic disease, chronic pulmonary 
disease, chronic intestinal disease, hypertension, 
coagulopathies, renal disease, brain disease) [37–39], or 
patients with immunocompromising conditions are at 
higher risk of severe SARS-CoV-2 infection [40, 41]. 
The major concern is that ACE2 is expressed in 72 
different cell types [42]. The expression of ACE2 can 
be affected by factors such as sex, environment, 
comorbidities, medications (e.g., anti-hypertensives), 
interaction with genes of the renin-angiotensin system, 
and other pathways. Those different factors can affect 
the risk of infection with SARS-CoV-2 and determine 
the severity of the disease. The ACE2 enzyme is a 
negative regulator of the renin-angiotensin system 
(RAS) expressed in various organ systems, but ACE2 is 
also related with innate immunity (complement), 
inflammation, increased coagulopathy, cardiovascular 
disease, metabolic disease, etc.; being involved in so 
many fundamental functions, ACE2 is central in the 
pathogenesis of COVID-19, and it is not a surprise to 
find how COVID-19 can rapidly become a severe 
disease [43–45]. Possibly, vaccination is more 
challenging in populations having ACE2-related 
disorders because the immunogenicity of vaccines is 
diminished overall in these groups [46]. 
 
Innate immune response vs. COVID-19  
 
The innate immune response will be responsible for the 
early SARS-CoV-2 infection clearance in COVID-19. 
The innate response will be crucial for the development 
of clinical manifestations in the course and severity of 
this disease. Innate immune cells contribute to resolving 
the first stages of COVID-19 infection by using their Fc 
receptor functions: complement-dependent cytotoxicity 
(classic, lectin-mediated, alternative), antibody-
dependent cellular phagocytosis, or cellular-dependent 
cytotoxicity [47].  
Elimination of the virus can occur through 
phagocytosis of virus-infected cells by alveolar 
macrophages via Fc-receptor or the activation of 
complement. Mannose-binding lectin (MBL), a pattern 
of recognition molecule, can initiate the lectin pathway 
of complement by binding to SARS-CoV-2. MBL is 
considered to contribute to host defense against SARS-
CoV, although it might be associated with thrombosis 
and coagulopathy in COVID-19 due to complement 
pathway hyperactivation in critical patients [48]. MBL 
deficiency is a susceptibility factor for the acquisition of 
SARS-type virus [49].  
The main viral antigen-presenting cells are DCs in the 
lungs and will constitute a bridge to link innate with 
adaptive immune response. Antigen-presenting cells are 
crucial to initiating an adaptive immune response 
directed by CD4+ T cell lymphocyte and cytotoxic T 
cell CD8+ [50, 51].  
The innate immune system type 1 can scan a variety 
of pattern recognition receptors to find highly 
conservative segments of SARS-CoV-2 [15]. Upon 
recognition of the virus through pattern recognition 
receptors by lung DCs and macrophages, INF-1 is 
secreted [41, 52]. Some types of monocytes expressing 
CD14 and CD62L can shift to secrete IFN and CCL2 
chemokines (monocyte chemoattractant protein-1, 
MCP-1) associated with a pro-fibrosis pattern seen in 
severe lung COVID-19. Natural killer cells and alveolar 
macrophages are the first-line defense of the innate 
immune response against SARS-CoV-2 [15].  
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The Th2 phenotype of an immune response drives 
goblet cells hyperplasia and epithelial cells turnover 
contributing to the integrity of the intestinal barrier 
function and building up the mucus layers locally [30]. 
Investigations are needed to confirm if cell-mediated 
Th2 and local goblet cells will contribute to the alveolar 
barrier and the development of protection against 
SARS-CoV-2. 
 
Adaptive immune response vs. COVID-19 
 
The CD4+ T cells are responsible for antibody 
production and the CD8+ T cells for T cell antiviral 
defense actions. SARS-CoV-2-specific CD4+ and 
CD8+ T cells are associated with mild symptoms and 
protective immunity during COVID-19 [51] due to 
early viral clearance.  
On the other hand, a rise in poor prognosis has been 
associated with anti-viral CD8+ T cells [47]. Antibodies 
interacting with the S protein can drive a neutralizing 
viral activity [53]. The S protein or a portion of it [54] 
have been used in models of the SARS-CoV-2 vaccines. 
The receptor-binding domain of the S protein interacts 
with the ACE2 receptor on human cells and permits cell 
invasion. Pneumocytes and enterocytes are the major 
target cells expressing ACE2 for SARS-CoV-2, playing 
a central role in SARS-CoV-2 replication. Antibodies 
induced by any anti-SARS-CoV-2 vaccine should give 
rise to the production of neutralizing and protecting 
anti-COVID-19 antibodies in the mucosal and other 
tissues environments [55]. An adequate level of 
neutralizing antibodies has been demonstrated in 
symptomatic and convalescent individuals, but they did 
not correlate with less severity of COVID-19 [56].  
A less severe COVID-19 has been associated with 
SARS-CoV-2-specific CD4+ and CD8+ T cells as part 
of the adaptive cellular immune response [51]. Cellular 
response induced by any anti-SARS-CoV-2 vaccine can 
drive towards preventing severe illness [57], reducing 
the number of hospitalizations and intensive care unit 
(ICU) admissions [54] due to SARS-CoV-2, and 
eventually reducing mortality due to complications for 
COVID-19 [54, 57]. These features could be important 
for helminth-coinfected COVID-19 individuals living 
in endemic areas, also for 65 years and older [58], and 
those with any co-morbidities severity of COVID-19 
[51]. 
 
COVID-19 severe infections 
 
COVID-19 severity is marked by a sudden health 
deterioration caused by an excessive pro-inflammatory 
immune response (cytokine storm) and/or an 
endothelial (macro and micro thrombus) response that 
leads to an acute respiratory distress syndrome (ARDS) 
in the lungs and disseminated intravascular coagulation 
in the whole organisms [59]. These two events are key 
to sudden COVID-19 increased severity [51, 59]. There 
are three severe clinical phases for COVID-19: the early 
inflammatory phase, the multisystem inflammatory 
phase, and the tail phase [31].  
It is well known that comorbidities (hypertension, 
obesity, diabetes, cardiovascular disease, others) and 
risk factors (smoking and vaping) can damage vascular 
endothelial glycocalyx and contribute to COVID-19 
severity (ARDS, disseminated intravascular 
coagulation, and Kawasaki disease shock syndrome). 
COVID-19 severity in a population can be estimated by 
measuring the raw fatality rate adjusting for 
demography (e.g. stratified by age) under-ascertainment 
[60]. The proportion of infected individuals hospitalized 
for COVID-19 and the number of days required to be 
discharged are other parameters used to estimate 
COVID-19 severity [60]. 
COVID-19 patients admitted to the ICU exhibit a Th2 
response pattern: IL-4, IL-5, IL-10, IL-13, and IL-25 
[56]. Most of these patients had peripheral eosinophils 
and basophils. Even though eosinophils can kill RNA 
viruses using RNases inside their granules, the presence 
of eosinophils and IL-6 has been reported as part of the 
cytokine storm cascade and COVID-19 fatal cases [61]. 
Events occurring from day 0 to 4 of symptoms are 
pivotal in the overall outcome of a COVID-19 patient. 
The measure of a score ratio of IL-6/IL-10 in ICU 
patients and obtaining the difference between day 0 to 
4, predicted the outcome on day 7 [62]. This score is 
named the Dublin-Boston [62] and permits to guide 
clinical decision-making by identifying risk outcomes 
in all types of COVID-19 hospitalized patients. The 
Dublin-Boston score could be an indirect measure of the 
double key role of IL-6 during the early stages of 
COVID-19 and short-term outcomes [62].  
A strong T cell CD8+ response that characterizes a 
Th1 pattern is seen in individuals that clear viral 
replication in 10 days or less. Th1 cells, induced by IL-
12 and producing IFN-γ, enhance the clearance of 
intracellular pathogens, like viruses. A delay or 
interference in the INF secretion (intracellular signals) 
as seen for helminths infections that release substances 
modulating early responding cells in innate immunity 
(DCs and macrophages) [15] could permit invasion and 
replication of the virus in the epithelial cells (lungs) and 
invasion to other organs [15]. The use of a SARS-
coronavirus animal model with delayed INF-γ has been 
used to describe a rapid virus replication and lung 
pathology progress up to death [64].  
 
Immunomodulation in helminth-COVID-19 
co-infections 
 
Intestinal helminths are a public health problem for 
underdeveloped countries [5, 7, 65–67] and suburban 
areas of developed countries. STH, Taenia spp., 
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considered as the four top-ranked helminths neglected 
tropical diseases. Immunomodulation possibilities in 
helminth-SARS-CoV-2 co-infections under the innate 
and adaptive response are illustrated in Table 1. 
 
 
Table 1 Summarized immunomodulation of innate and adaptive immune response to SARS-CoV-2 in 
helminth co-infections  
Immune 
response 
Enhance viral protection Increase viral pathology/severity in disease 
Innate 1. Dependent PRR toll-like.  
2. CLR → ↓ viral. 
3. NOD domain NOD→ ↓ viral. 
4. Inflammasome → ↓ viral. 
5. RIG-I, MDA-5, CLR, NOD recognize highly 
conserved residues of SARS-CoV-2 → ↓ viral. 
6. Vitamin D → ↑ Cathelicidin LL-37 and 
defensins.  
7. AMP → ↓ viral. 
1. ↑ Alternative complement pathway by protein N 
of SARS-CoV-2 → cytokine storm development ↑ 
IL-6, ↑ IL-1-β ↑ GMCSF, ↑ TNF-α.  
2. ↑ Chemokines, ↑ monocytes, ↑ neutrophils, and ↑ 
eosinophils.  
3. ↑ Mutations in spike (glycosylated region) → 
difference in virulence, viral fusion, and mortality, 
for instance, B1 clade (west coast of US) vs A2a 
clade (east coast of US).  
Adaptive 1. Clonal expansion of CD8+ T cells in 
individuals with mild to moderate symptoms 
can clear SARS-CoV-2 from the lungs.  
2. A brief inflammatory phase → cleanup of 
virus-infected cells by alveolar macrophages, 
secretion of surfactant and IL-10, and TGF-β → 
anti-inflammatory lung microenvironment.  
3. IL-4: ↑ T cell CD8+ (memory). ↑ T cell 
CD8+ antigen-specific (antiviral, only in 
murine model). 
1. ↑ Th2 immune response: T helper cells and Th2 
cytokines: ↑ IL-4, ↑ IL-5, ↑ IL-9, and ↑ IL-13. ↑ Lung 
macrophages. ↑ Pulmonary eosinophils. ↑ IL-10 → 
↓ Th1 response.  
2. ↓ CD4+ T cells expressing INF-γ and TNF-α by 
Th2 cytokines. 
3. ↑ Defective INF-γ secretion by CD4+ T cells in 
patients with COVID-19 severe symptoms.  
4. Immune modulation towards Th2 → suppression 
of immune response against intracellular pathogens 
(malaria, tuberculosis, and HIV/AIDS). 
5. ↑ Eosinophils and ↑ IL-6 → cytokine storms → 
fatal COVID-19 ↑ Th2 immune response in blood 
smear of patients requiring intensive care for 
COVID-19: ↑ eosinophils, ↑ basophils, ↑ immature 
plasma cells, and ↓ T cell lymphocytes. 
SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2; PRR, pattern recognition receptors; NOD, 
nucleotide-binding and oligomerization domain; CLR, C-type lectin receptors; RIG-I, retinoic acid inducible gene I, 
functions as a cytosolic pattern recognition receptor; MDA-5, melanoma differentiation-associated gene 5 is a 
cytosolic receptors for dsRNA; AMP, anti-microbial peptides; CD8+, subpopulation of MHC class I-restricted T cell 
with CD8 co-receptor; IL, interleukin; TGF-β, transforming growth factor beta; GM-CSF, granulocyte-macrophage 
colony stimulatory factor; TNF-α, tumor necrosis factor alpha; B.1, one of major lineage of SARS CoV-2 (B.1 clade) 
and includes Alpha (B.1.1.7), Beta (B.1.315), Delta (B.1.617.2) and Gamma (B.1.1.28.1, an alias of P.1) variants; 
A2a, is a lineage of SARS CoV-2 (A.2 clade) with a point mutation in the spike protein (D614G); Th1, T helper type 
1 cells are a lineage of CD4+ effector T cell and secrete IFN-γ, IL-2, IL-10, and TNF-alpha/beta; CD4+ subpopulation 
of MHC class II T-helper T cell with CD4+ receptor; Th2, T helper type 2 cells are CD4+ effector T cell and secretes 
IL-4, IL-5, IL-9, IL-13, and IL-17E/IL-25; COVID-19, coronavirus disease 2019; HIV/AIDS human 
immunodeficiency virus infection and acquired immune deficiency syndrome. Data extracted from the following 
references [15, 17, 18, 35, 46, 47, 56, 87–89]. 
Helminths can suppress the inflammatory responses 
occurring during infections by protozoa, bacteria, and 
viruses [58]. A human host infected with helminth 
before infection by SARS-CoV-2 is responding to the 
helminth infection with a type 2 innate and adaptive 
immune response [14]. SARS-CoV-2 replication and 
survival inside this host could be enhanced or inhibited 
by this Th2 pattern [17, 47, 68]. A helminth/SARS-
CoV-2 co-infection could lead to a defective T cell 
response and low levels of IFN-I. Additionally, 
reprogramming macrophages from macrophage type 1 
to type 2, as a tolerance mechanism, has been previous 
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documented by other authors to be elicited by 
Trichinella spiralis [69]. This supportive environment 
for SARS-CoV-2 replication has been reported in 
COVID-19 patients with a severe progression 
characterized by lower levels of INF-γ and TNF-α in 
CD4+ T cells [50]. 
Complexity in the overlapping events in the natural 
history of the COVID-19 and participation of different 
cofactors [70] can deliver a varicolored infection 
outcomes and some some infected people have a fatal 
end. Five COVID-19 phases (the viral symptom phase, 
the early inflammatory phase, the secondary infection 
phase, the multisystem inflammatory phase, and the tail 
phase) have been described [31]. 
Helminth co-infections can compromise the host 
immunological outcome and a spectrum response can 
be seen during all five phases of COVID-19.  
Immunomodulation created by a helminth-viral co-
infection, specifically occurring for lung-cycle STH, 
could permit a shorter pre-asymptomatic phase and 
facilitate invasion, replication, and progression of the 
viral infection [71]. The downregulation of the innate 
and adaptive immune response takes an important role 
in the co-evolution of both infections (Table 1). Evasion 
mechanisms can be elicited simultaneously by the virus 
and the helminth [58]. All types of coronavirus, 
including SARS-CoV-1 and Middle East respiratory 
syndrome coronavirus (MERS-CoV), use immune 
evasion mechanisms to circumvent the innate and 
adaptive immunity [50], in particular when escaping 
detection of pattern recognition receptors by the host 
innate immune response in early SARS-CoV-2 
infection [50].  
The initiation and maintenance of the symptomatic 
COVID-19 period would be characterized by high 
levels of neutralizing antibodies in the acute and 
convalescence period. The presence of neutralizing 
antibodies was not associated with less disease severity 
[51]. 
From the point of view of the adaptive immune 
response, SARS-CoV-2 can make use of antibody-
dependent enhancement (ADE) mechanisms to evade 
the immune system. The virus may use ADE and 
macrophages Fc receptor to enter and re-program host 
cells for proinflammatory cytokines production-like IL-
6, that would support virus replication and survival [59]. 
Anti-inflammatory cytokines type 2-like IL-10 are 
frequently present in helminth-infected humans [71] 
and could play an important role in stopping the 
cytokine tissue damage in the early and multisystem 
inflammatory phases. IL-6 promotes the production of 
IL-27 by lung macrophages in a host infected by the 
respiratory syncytial virus [52]; at the same time, IL-27 
promotes the local maturation of regulatory T cells. IL-
6 could have a double key role as a proinflammatory 
cytokine and as a local regulation of lung Th1 response. 
Similarly, IL-6 in SARS-Cov-2 infection could limit 
infection and viral lung immunopathology by inducing 
the production of IL-27. A study demonstrates high 
levels of IL-6 and a decreased levels of IL-27 in 
psoriasis patients at risk for COVID-19. None of the 
patients developed severe symptoms or complications 
post-COVID-19. IL-27 levels did not lead to an 
increased risk for SARS-CoV-2 infection [72].  
Another cytokine with a dual role is IL-33. IL-33 is 
secreted by the lung DCs. The helminth mouse model 
of Nippostrongylus brasiliensis demonstrated that IL-33 
can promote type 2 inflammation in epithelial cells by 
stimulating ILC-2 but also can drive immunoregulation 
through expansion of Treg by DCs. It is not clear if the 
downregulation of innate and cellular adaptive immune 
response against SARS-CoV-2 driven by lung DCs can 
play an anti-inflammatory role in the natural history of 
COVID-19. Tuft cells -present in the intestine and 
lungs- can produce IL-25 and IL-33 in response to 
helminth and elicit the production of ILC2s, which 
produce IL-4 and IL-13 [14].  
 
COVID-19 infections in helminth endemic 
areas 
 
The immune system will respond in a different way to 
helminths and viruses after overpassing the host 
epithelial barriers. In general, helminths establish long-
lived, chronic infections characterized by broad down-
modulation of both the innate and adaptive arms of host 
immunity [20].   
The burden and impact data for COVID-19 for each 
country is still not accurate because this pandemic is an 
ongoing situation. America, followed by Europe and 
South-East Asia has been the most affected regions in 
the world for COVID-19.  
STH burden and impact data can vary from one 
country to another. And in the same country, we can 
find areas of high or low transmission of helminths. 
Each country has a different reality for helminth 
prevalence and species, in some cases, there is a marked 
difference between regions in the same country, for 
instance, Brazil.  
From an epidemiological and public health point of 
view, the helminth species present in each endemic area 
will influence the outcome of a helminth-COVID-19 
co-infection. As stated above, a helminth infection can 
determine protection or severity against a COVID-19 in 
individuals and populations co-infected with helminths, 
specifically with STH. To address the status of 
protection or severity in a co-infected region will permit 
to plan public health measures adaptable to that region, 
for instance, deworming, type of COVID-19 vaccine to 
be used, and other preventable measures.  
If the development of protection against SARS-CoV-
2 infection is feasible in cases of chronic helminth 
infections in immunomodulated hosts, global 
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fatal COVID-19 cases. This hypothesis has been 
documented in Sub-Saharan Africa with high STH 
prevalence where co-infection promotes a low lethality 
for COVID-19 [58, 73]. On the other hand, India, an 
Asiatic country with a wide range of endemic helminth 
areas is occupying 2nd place worldwide, after the 
United States of America, with 30,082,778 confirmed 
cases of COVID-19 and 390,660 deaths, reported to 
WHO [74]. 
The STH prevalence in India varies from high to low 
depending on the helminth species (high for Ascaris 
lumbricoides, low for Trichuris trichiura, and 
intermediate and low for hookworm). The most 
common STH is A. lumbricoides. STH prevalence is 
high in some regions (Bahir, Tamil Nadu, and Jammu 
and Kashmir); it is intermediate in Maharashtra and low 
in Delhi’s [75]. The immunomodulation outcome for 
helminth-COVID-19 co-infections in those regions 
shows the evident difference among regions in which 
regions with high STH prevalence, mainly by A. 
lumbricoides (Bahir), COVID-19 severity appeared to 
be prevented, whereas in the Delhi region with lower 
STH prevalence more severe cases for COVID-19 were 
occurring (Figure 1). Regions with high to intermediate 
prevalence for STH are more probable to develop mild 
to moderate cases of COVID-19. The data for India 
(Figure 1) was extracted from the total death table of the 
center for system science and engineering at John 
Hopkins University [76] of the tracking coronavirus in 
India: Latest Map and Case Count document [77]. The 
COVID-19 severity in India has not been estimated by 
measuring the raw fatality rate nor adjusting for by age, 
so we have plotted COVID-19 severity (reported as a 
share in population deaths) vs. classes of severity 
intensities for STH [75].  
In Latin America, Brazil is 3rd placed worldwide and 
1st place in this region for COVID-19 infections 
(18,054,653) and deaths (504,717) [74]. Like India, 
Brazil is also an endemic country for STH in South 
America, Ascaris lumbricoides and hookworm having 
intermediate (20%–50%) to the high percentage (50%–
100%) of prevalence. However, the percentages of 
prevalence in Brazil appear lower than those seen in 
India. By contrast, the rates of lethality for COVID-19 
are higher than those seen in India for some states. 
Minas Gerais, a very low-income state, has a high 
prevalence of A. lumbricoides and intermediate 
prevalence of hookworm [78]. The data about the share 
in population deaths for COVID-19 severity in Brazil’s 
states was not accessible. Nonetheless, the lethality rate 
for Minas Gerais appears inexplicably very high (25.49) 
compared to Rio de Janeiro state (5.81); Rio de Janeiro 
has a low prevalence for all STH [78].  
If the hypothesis about a protective status from 
SARS-CoV-2 during co-infection with helminths and 
diminished immunopathology is viable, three new 
questions should arise to understand viral clearance and 
resolution for COVID-19:  
 Which immunomodulation would be more 
important - inhibition of Th1 or increase of Th2 
immune response? 
 Which would be the best timeline in the natural 
history of the disease to stop immune pathology?  
 Would this status be helpful for a host with 
comorbidities, like diabetes and obesity?  
Further investigation should be done to demonstrate 
if this can be an in vivo possibility for the helminth-
SARS-CoV-2 model [18]. 
The diversity of helminth/other pathogens co-
infection results in human hosts are such that is not easy 
to make general conclusions from these results. Table 2 
summarizes how some co-infections can compromise 
the host immunological pathogenesis outcome or 
contribute to resolving, for instance, a viral infection.  
Animal models and experimental STH infections 
have limitations in generating the natural immunity and 
long-live lasting history of most STH infections in 
endemic areas as occurring in nature. Nonetheless, 
helminths can often affect the evolution of co-infection 
by making animals more resistant to other pathogens in 
which protection is mediated by the Th2-like response 
and more susceptible to other pathogens in which 
protection is mediated by the Th1-like response [18, 26]. 
Other pathogens can also influence the immune 
response against helminths, depending on which 
infection was installed first [26]. 
 
COVID-19 vaccinations in helminth endemic 
areas 
 
A COVID-19 vaccine should impel an innate immune 
response in the respiratory system followed by an 
adaptive response to impede SARS-CoV-2 infection. 
To trigger mucosal immunity the inoculation of the 
vaccine should be via a respiratory mucosal route [28]. 
This route is not feasible for all vaccine models. A 
CD4+ T cell Th2 respiratory mucosal 
microenvironment is present in individuals infected by 
helminths because most geohelminths have larvae stage 
life cycle migrating through the lungs [79, 80]. An 
individual infected by helminth has a different 
respiratory mucosal microenvironment before the 
COVID-19 vaccine is administered. It is not clear if the 
anti-inflammatory immune status present in a helminth 
infection will diminish in COVID-19 vaccinated hosts 
and if the post-vaccine immune system can prevent a 
cytokine storm outcome. 
Helminths may influence vaccine efficacy by 
modulating the host immune response when Th1-like 
and cellular-dependent responses are required for the 
2nd -arrived pathogen, as would be the case for a 
helminth-COVID-19 co-infection (Table 3). The 
immunomodulatory effects of helminth infections can 
mitigate vaccination efficacy [46, 79]. Chronic 
REVIEW 
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helminthiasis has a more negative impact on 
immunization than acute disease [80]. Furthermore, 
individuals could be polyparasitized and it will be 
necessary to evaluate the overall effect resulting from 
immunomodulation for more than one parasite.  
An excellent example is the use of the Litomosoides 
sigmodontis infected mice model to demonstrate how 
helminth infection reduces the quantity and quality of 
antibody responses to vaccination against seasonal 
influenza (Table 2) [52, 55]. In helminth-infected mice, 
IL-10 was responsible for this viral immunosuppression, 
which was partially repealed by the in vivo blockade of 
the IL-10 receptor by a neutralizing anti-IL-10 receptor 
monoclonal antibody after Influenza vaccination, 
restoring immunoglobulins response. The sustained 
expansion for over 90 days of IL-10 producing-CD4+-
type 1 regulatory T cells inhibited the production of 
viral-specific antibodies (IgG1, IgG2b, and IgG2c) [81].  
Helminth co-infection impact over viral vaccination 
can be diminished by using either antiparasitic 
medication before vaccination or several boosts to 
induce a T cell help response and neutralizing 
antibodies as part of the adaptive immune response. The 
first alternative is more feasible. Deworming can 
decrease SARS-CoV-2 viral load and improve T cell 
CD8+ in the lung microenvironment. Mass deworming, 
as recommended by WHO for endemic areas [82] 
before the implementation of the COVID-19 vaccine 
will be a pharmacological intervention that could 
improve anti-SARS-CoV-2 protection in helminth 
infected individuals and future trials could elucidate  
 
 
Figure 1 STH/COVID-19 co-infections and immunomodulation outcome in India. This is a partial representation 
of COVID-19 severity (in terms of deaths) in four helminth-endemic Indian regions with different STH prevalence 
percentages (%) [75]. Bahir region: high STH prevalence and at least 1 in 10,886 residents died; possible protective 
immunomodulation and less severe cases for COVID-19. Jammu and Kashmir region (high to intermediate STH 
prevalence), and Maharashtra region (intermediate to low STH prevalence) with 1 in 2,874 and 1 in 976 fatalities, 
respectively; moderate to severe cases for COVID-19. Delhi region: with low STH prevalence and more severe cases 
for COVID-19 (1 in 673 deaths). Since the beginning of the pandemic, at least 1 in 3,486 residents have died from 
COVID-19 in India. And a total of 391,981 deaths up to June 23, 2021 [74, 76, 77]. STH, soil-transmitted helminth; 
COVID-19 coronavirus disease 2019. 
Table 2 Co-infections compromise the host immunological pathogenesis outcome and infections 
Host Species Parasite Virus Effect Reported mechanisms 
















Mice Fasciola hepatica Trematode SARS-
CoV-2 
Modulation of hyper 
inflammation 
reactions in the 




CoV-2 entry into host 
cells → induces anti-




Trematode HIV ↑ Transmission of 
HIV. 
↓ CD4 T cells. 
Deworming → decreases 
HIV viral load and ↑ 








Trematode HPV Helminth-induced 
immune response ↑ 
HPV disease 
progression. 
Chronic S. mansoni 
infection ↓ protective 
HPV-specific IgG 
antibodies induced by 
vaccination. Treatment of 
schistosomiasis with PZQ 
before HPV vaccination 






Nematode RSV Helminth-induced 
immune response ↓ 
RSV pulmonary 
disease. 
↑ Type I interferon 
signaling protects against 
the pulmonary virus 
infection through 






FV Helminth infection 
interfered with the 
control of the 
retroviral infection. 
Increased viral loads in 
co-infected mice were 
associated with ↓ titers of 
neutralizing FV-specific 









Helminth infection ↓ 
virus load. 




SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2; HIV, human immunodeficiency virus; HPV, 
human papillomavirus; RSV, respiratory syncytial virus; FV, friend virus retrovirus. Data extracted from the 
following references, T. spiralis [90]; F. hepatica [68]; S. mansoni [19, 91]; H. polygyrus [92]; L. sigmondontis [93]; 
Echinoparyphium sp. [94].  
 
Table 3 Course of COVID-19, previous helminth co-infection and after COVID-19 vaccination 
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COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2; PRR, 
pattern recognition receptors; IL, interleukin; CD8+, subpopulation of MHC class I-restricted T cell with CD8 co-
receptor; Th2, T helper type 2 cells are CD4+ effector T cell and secrete IL-4, IL-5, IL-9, IL-13, and IL-17E/IL-25; 
TGF-β, transforming growth factor beta; IFN-γ, interferon gamma; TNF-α, tumor necrosis factor alpha.  
 
COVID-19 vaccination impact [81, 83]. Schistosoma 
infections are associated with increase transmission of 
HIV and deworming decreased HIV viral load and 
improved CD4+ counts among HIV-infected 
individuals [19]. 
A placebo-controlled doubleblind trial conducted in 
Central Africa (Gabon) demonstrated the effect over the 
immune response after a single dose of albendazole 
(400 mg) before influenza immunization. Children in 
the treated group had higher levels of total antibodies, 
even though specific immunoglobulin A titles were not 
significantly different. Higher titers of immunoglobulin 
A, IgG1, and IgG3 against both influenza A strains and 
memory B-cell response were modestly higher in the 
treated group [83]. Antibody levels can be different and 
influenced by the burden and type of prevalent parasite 
in the endemic population. The use of alternative 
treatment schedules- single vs two or more doses before 
vaccination is another variable to consider in future 
trials.  
Not always anti-helminthic treatment can modify the 
immune response unbalance. After 16 years of 
ivermectin treatment, a negative Th1/Th2 response 
persisted in Oncocerca volvulus’s infected population 
characterized by high levels of IL-10, IgG1, and IgG4 
[84]. 
Some developing countries include the use of the 
Bacillus Calmette-Guérin (BCG) vaccine in their 
national control program. It has been hypothesized that 
BCG vaccination can epigenetically modulate the innate 
immune response leading to an enhanced cytokine 
response by TNF-α, IL-1β, and IL-6. BCG has been 
demonstrated to reduce viral titers (Influenza, vaccinia, 
and Herpes virus) in infected mice by 
immunomodulation [85]. 
Other alternative strategies to counterbalance the 
immunomodulatory effects of helminths in co-
infections have been proposed before proceeding to 
anti-COVID-19 vaccinations in the helminth endemic 
areas, such as the use of a specific adjuvant [[26], use of 
Immune 
response 
SARS-CoV-2 infection SARS-CoV-2 and previous 
chronic helminth infection 
Previous chronic helminth 
infection and anti- SARS-CoV-
2 vaccine  
Innate  Rapid reduction of viral load 
by PRR and innate immune 
cells. 
Impair reduction of viral load 
by the effect of parasite 
immune evasion mechanisms.  
If vaccine ↑ T cell response, 
anti-helminth response impairs 
this response, COVID-19 
manifest. If the vaccine ↑ 
neutralizes and or protects 
antibodies, COVID-19 may not 
manifest. 
Adaptive  IL-6/IL-10 is positive. Viral 
infection resolution by Th1 
type immune response in 
lungs: macrophages and 
CD8+ T cells clone 
expansion. 
IL-6/IL-10 is negative. 
Immune response in lungs 
inhibits Th1 response. 
↑Pulmonary eosinophils. Low 
INF-γ and TNF-α. 
IL-6/IL-10 may be negative or 
positive. Helminth co-infection 
immune-suppression can alter 
COVID-19 vaccine cellular and 





lung microenvironment by 
IL-10, surfactant, and TGF- 
β.  
↑ Excretory/Secretory 
helminth products: ↑ Th2-type 
anti-inflammatory lung 
microenvironment products by 
IL-10 and IL-33, can avoid 
cytokine storm and/or impair 
viral resolution. 
Mild symptoms and Th2-type 
anti-inflammatory can avoid 
cytokine storm.  
Moderate symptoms and anti-
COVID-19 vaccine antibodies 
would ↓ viral load and possibly 
disease progression. 
Severe symptoms and 
suppression of vaccine-induced 
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a human monoclonal antibody to block SARS-CoV-2 
infection, immune-modulating therapies, and massive 
deworming of endemic communities [15]. 
 
Conclusions and future perspectives 
 
Preliminary studies of helminth endemic communities 
before COVID-19 vaccination should include 
community information about the implementation of 
preventive measures. Helminth co-infections may 
downregulate the efficient immune response against 
SARS-CoV-2 in the early stage of the infection, thereby 
increasing morbidity and mortality in COVID-19 
patients. Helminth infections can suppress the immune 
responses and can mitigate SARS-CoV-2 vaccine 
efficacy [79].  
To know the status of protection or severity in a co-
infected region will permit to plan public health 
measures adaptable to a specific area, for instance, 
deworming, type of COVID-19 vaccine to be used, and 
other preventable measures.  
We propose the previous evaluation of the IL-6/IL-
10 score in helminth endemic communities, to predict 
vaccine response in helminth neglected tropical disease 
areas. It may be useful to map around the world whether 
helminth-infected communities will be susceptible to 
COVID-19 infection or able to inhibit it after 
vaccination against COVID-19. 
The outcome, equilibrium, and timeline of each 
proinflammatory/anti-inflammatory cytokine (IL-6/ IL-
10 ratio) can elucidate how helminth previous infection 
can influence the natural history of COVID-19 disease 
and immune response after COVID-19 vaccination. 
A re-installation of an anti-inflammatory lung 
microenvironment is crucial for less severe disease, as 
confirmed by some studies [86]. Th2 pattern cytokines, 
like IL-10, can inhibit the inflammatory cascade of 
cytokines in those individuals simultaneously 
coinfected by helminths and SARS-CoV-2:  
 Individuals with mild symptoms can have a brief 
inflammatory phase followed by a cleanup of 
virus-infected cells by alveolar macrophages, 
secretion of surfactant and IL-10, and transforming 
growth factor-beta (TGF-β). 
 Th2 pattern cytokines predominate in long-term 
helminth infected individuals and helminth 
endemic communities. This pattern is also 
dependable on helminth species and host-parasite 
burden. 
 The production of IL-6 followed by IL-27 permits 
the recruitment and well-functioning of a cellular 
adaptive response commanded by regulatory T 
cells as key for stopping SARS-CoV-2 replication 
and limiting the infection period reaching a full 
convalescence in COVID-19. 
We have hypothesized here that the innate and the 
adaptive host immune response against the COVID-19 
vaccine can be different (enhancing, deteriorating, or no 
modification) in helminth-infected vs. non-helminth- 
infected hosts. Examples discussed in this work suggest 
that the hypothesis may have relevant epidemiological 
and anti-COVID-19 vaccination implications in STH 
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